Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Neoplasm Metastasis 2 Uterine Cervical Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 52 Radiotherapy 24 Bevacizumab 23 Radiation 10 Magnetic Resonance Spectroscopy 7 Lomustine 7 Carmustine 7 Radiosurgery 6 Surgical Procedures, Operative 5 Irinotecan 5 Aminolevulinic Acid 5 Radiotherapy, Intensity-Modulated 4 Nivolumab 4 Ipilimumab 4 Erlotinib Hydrochloride 4 Cilengitide 4 vocimagene amiretrorepvec 3 vitespin 3 sargramostim 3 poly ICLC 3 pembrolizumab 3 fluoromisonidazole 3 carmustine, poliferprosan 20 drug combination 3 Vorinostat 3 TPI-287 3 O(6)-benzylguanine 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Flucytosine 3 Dynamic Contrast Enhanced Magnetic Resonance Imaging 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Glioblastoma × Automobiles × Clear all

NCT02664363 2023-02-17

ExCeL

Duke University

Phase 1 Terminated

3 enrolled 8 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡